TARDBP and proteostasis deficiencies: Recent studies have demonstrated that different structural domains in TDP-43 could be exploited and targeted to develop drugs to stabilize the native state of TDP-43, which could constitute a viable and effective strategy for treating TDP-43 proteinopathies [113] (Fig. 4).